Copyright
©The Author(s) 2004.
World J Gastroenterol. Mar 1, 2004; 10(5): 649-653
Published online Mar 1, 2004. doi: 10.3748/wjg.v10.i5.649
Published online Mar 1, 2004. doi: 10.3748/wjg.v10.i5.649
Table 1 Description of cases
Age (yr) | |
Median | 58 ± 14.1 |
Range | 21-86 |
Sex | |
Male | 81 |
Female | 18 |
Modality of diagnosis | |
Cytological/histological | 33 |
Imaging + AFP > 400 ng/mL | 30 |
Imaging + AFP < 400 ng/mL or unknown | 36 |
Cirrhosis | |
Absent | 5 |
Present | 80 |
Chronic parenchymalds’ | 14 |
Causes of liver disease | |
Hepatitis B | 58 |
Hepatitis C | 22 |
Hepatitis B + C | 5 |
Non B and Non C | 6 |
Alcoholic | 1 |
Child-Pugh stage (unknown = 2) | |
A | 43 |
B | 33 |
C | 21 |
AFP (ng/mL) (unknown = 10) | |
10 < | 17 |
11-400 | 33 |
400 | 39 |
Portal vein thrombosis (unknown = 3) | |
No | 46 |
Yes | 50 |
Pre ThalidomideTreatment (unknown = 7) | |
No | 30 |
Yes | 72 |
Surgery | 11 |
PEI | 16 |
TACE | 49 |
Radiation | 6 |
Chemotherpay | 3 |
Table 2 Okuda staging for HCC
Point | 0 | 1 |
Size of tumor | < 50% of liver | > 50 % |
Ascites | No | Yes |
Albumin | ≥ 3 | < 3 |
Bilirubin | < 3 | ≥ 3 |
Stage I: 0 | II: 1 or 2 | III: 3 or 4 |
Table 3 CLIP scoring system
Scores Variables | 0 | 1 | 2 |
Child-pugh stage | A | B | C |
Tumor morphology | Unninodular | Multinodular | Massive |
and extension | and extension | or extension | |
≤ 50% | ≤ 50% | > 50% | |
AFP | < 400 | ≥ 400 | |
Portal vein thrombosis | No | Yes |
Table 4 Hepatocellular carcinoma stage and survival time, Okuda stage and survival time
Group | Stage | MSD | |||
I | II | III | |||
A (n = 19) | Case No. | 5 | 9 | 5 | |
Survival days | 161 | 26.8 | 10.5 | 25.2 | |
B (n = 76) | Case No. | 19 | 41 | 16 | |
Survival days | 171.5 | 136.5 | 47.3 | 108.5 |
Table 5 Hepatocellular carcinoma stage and survival time, CLIP classification and survival time
Group | Score | |||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | ||
A (n = 20) | Case | 0 | 2 | 2 | 2 | 8 | 5 | 1 |
Survival days | 220.5 | 49 | 42 | 35 | 12.3 | 11 | ||
B (n = 76) | Case | 1 | 8 | 20 | 20 | 15 | 9 | 3 |
Survival days | > 345 | 301 | 150.5 | 106.8 | 96.2 | 59.5 | 19.3 |
Table 6 Response rate of hepatoma treated with thalidomide
- Citation: Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10(5): 649-653
- URL: https://www.wjgnet.com/1007-9327/full/v10/i5/649.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i5.649